A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 14 (final count)
- Started
- Aug 2, 2022
- Main results expected
- Feb 8, 2024
- Fully finished
- Feb 8, 2024
- Results posted
- Feb 27, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events
Measured over: From first dose to 100 days post last dose (Approximately up to 14 Months)
Number of Participants With Serious Adverse Events
Measured over: From first dose to 100 days post last dose (Approximately up to 14 Months)
Number of Participants With Treatment Related Adverse Events
Measured over: From first dose to 100 days post last dose (Approximately up to 14 Months)
Number of Participants With Treatment Related Serious Adverse Events
Measured over: From first dose to 100 days post last dose (Approximately up to 14 Months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05297565 · record last updated 2025-02-27 · checked 2026-11-09 15:47 UTC